FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2122492414> ?p ?o ?g. }

• W2122492414 endingPage "2302" @default.
• W2122492414 startingPage "2296" @default.
• W2122492414 abstract "Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor, for which no effective standard systemic treatment exists for patients with unresectable disease. Cediranib is a potent, oral small-molecule inhibitor of all three vascular endothelial growth factor receptors (VEGFRs).We conducted a phase II trial of once-daily cediranib (30 mg) given in 28-day cycles for patients with metastatic, unresectable ASPS to determine the objective response rate (ORR). We also compared gene expression profiles in pre- and post-treatment tumor biopsies and evaluated the effect of cediranib on tumor proliferation and angiogenesis using positron emission tomography and dynamic contrast-enhanced magnetic resonance imaging.Of 46 patients enrolled, 43 were evaluable for response at the time of analysis. The ORR was 35%, with 15 of 43 patients achieving a partial response. Twenty-six patients (60%) had stable disease as the best response, with a disease control rate (partial response + stable disease) at 24 weeks of 84%. Microarray analysis with validation by quantitative real-time polymerase chain reaction on paired tumor biopsies from eight patients demonstrated downregulation of genes related to vasculogenesis.In this largest prospective trial to date of systemic therapy for metastatic ASPS, we observed that cediranib has substantial single-agent activity, producing an ORR of 35% and a disease control rate of 84% at 24 weeks. On the basis of these results, an open-label, multicenter, randomized phase II registration trial is currently being conducted for patients with metastatic ASPS comparing cediranib with another VEGFR inhibitor, sunitinib." @default.
• W2122492414 created "2016-06-24" @default.
• W2122492414 creator A5003847273 @default.
• W2122492414 creator A5007831491 @default.
• W2122492414 creator A5009905507 @default.
• W2122492414 creator A5033145217 @default.
• W2122492414 creator A5041200743 @default.
• W2122492414 creator A5044239219 @default.
• W2122492414 creator A5046416890 @default.
• W2122492414 creator A5058978836 @default.
• W2122492414 creator A5064141830 @default.
• W2122492414 creator A5066585382 @default.
• W2122492414 creator A5073401889 @default.
• W2122492414 creator A5080736692 @default.
• W2122492414 creator A5082080836 @default.
• W2122492414 creator A5090468019 @default.
• W2122492414 date "2013-06-20" @default.
• W2122492414 modified "2023-09-27" @default.
• W2122492414 title "Cediranib for Metastatic Alveolar Soft Part Sarcoma" @default.
• W2122492414 cites W1572876072 @default.
• W2122492414 cites W1769310585 @default.
• W2122492414 cites W1971762239 @default.
• W2122492414 cites W1985429138 @default.
• W2122492414 cites W1988045521 @default.
• W2122492414 cites W2007624605 @default.
• W2122492414 cites W2012921981 @default.
• W2122492414 cites W2039013742 @default.
• W2122492414 cites W2085053752 @default.
• W2122492414 cites W2094337993 @default.
• W2122492414 cites W2097373408 @default.
• W2122492414 cites W2106855098 @default.
• W2122492414 cites W2108921615 @default.
• W2122492414 cites W2133365073 @default.
• W2122492414 cites W2137758263 @default.
• W2122492414 cites W2139248078 @default.
• W2122492414 cites W2146355396 @default.
• W2122492414 cites W2147712199 @default.
• W2122492414 cites W2154056804 @default.
• W2122492414 cites W2165630767 @default.
• W2122492414 cites W2169500410 @default.
• W2122492414 cites W2340136319 @default.
• W2122492414 cites W298677108 @default.
• W2122492414 cites W4105886 @default.
• W2122492414 doi "https://doi.org/10.1200/jco.2012.47.4288" @default.
• W2122492414 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3677840" @default.
• W2122492414 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23630200" @default.
• W2122492414 hasPublicationYear "2013" @default.
• W2122492414 type Work @default.
• W2122492414 sameAs 2122492414 @default.
• W2122492414 citedByCount "179" @default.
• W2122492414 countsByYear W21224924142013 @default.
• W2122492414 countsByYear W21224924142014 @default.
• W2122492414 countsByYear W21224924142015 @default.
• W2122492414 countsByYear W21224924142016 @default.
• W2122492414 countsByYear W21224924142017 @default.
• W2122492414 countsByYear W21224924142018 @default.
• W2122492414 countsByYear W21224924142019 @default.
• W2122492414 countsByYear W21224924142020 @default.
• W2122492414 countsByYear W21224924142021 @default.
• W2122492414 countsByYear W21224924142022 @default.
• W2122492414 countsByYear W21224924142023 @default.
• W2122492414 crossrefType "journal-article" @default.
• W2122492414 hasAuthorship W2122492414A5003847273 @default.
• W2122492414 hasAuthorship W2122492414A5007831491 @default.
• W2122492414 hasAuthorship W2122492414A5009905507 @default.
• W2122492414 hasAuthorship W2122492414A5033145217 @default.
• W2122492414 hasAuthorship W2122492414A5041200743 @default.
• W2122492414 hasAuthorship W2122492414A5044239219 @default.
• W2122492414 hasAuthorship W2122492414A5046416890 @default.
• W2122492414 hasAuthorship W2122492414A5058978836 @default.
• W2122492414 hasAuthorship W2122492414A5064141830 @default.
• W2122492414 hasAuthorship W2122492414A5066585382 @default.
• W2122492414 hasAuthorship W2122492414A5073401889 @default.
• W2122492414 hasAuthorship W2122492414A5080736692 @default.
• W2122492414 hasAuthorship W2122492414A5082080836 @default.
• W2122492414 hasAuthorship W2122492414A5090468019 @default.
• W2122492414 hasBestOaLocation W21224924142 @default.
• W2122492414 hasConcept C121608353 @default.
• W2122492414 hasConcept C123012128 @default.
• W2122492414 hasConcept C126322002 @default.
• W2122492414 hasConcept C142724271 @default.
• W2122492414 hasConcept C143998085 @default.
• W2122492414 hasConcept C167734588 @default.
• W2122492414 hasConcept C185592680 @default.
• W2122492414 hasConcept C202751555 @default.
• W2122492414 hasConcept C2776694085 @default.
• W2122492414 hasConcept C2777025900 @default.
• W2122492414 hasConcept C2777666782 @default.
• W2122492414 hasConcept C2778256501 @default.
• W2122492414 hasConcept C2778822529 @default.
• W2122492414 hasConcept C2779490328 @default.
• W2122492414 hasConcept C2779984678 @default.
• W2122492414 hasConcept C31760486 @default.
• W2122492414 hasConcept C535046627 @default.
• W2122492414 hasConcept C55493867 @default.
• W2122492414 hasConcept C60781801 @default.
• W2122492414 hasConcept C71924100 @default.
• W2122492414 hasConcept C90924648 @default.

• next